多伟托（Doravirine/拉米夫定/替诺福韦艾拉酚胺富马酸盐）在初治 HIV-1 及传播型非核苷类逆转录酶抑制剂耐药突变患者中的疗效和安全性。
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
机构信息
Department of Medicine, University of Saskatchewan, Regina, Saskatchewan, Canada.
Whitman-Walker Institute, Washington, DC.
出版信息
J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153.
Abstract
Supplemental Digital Content is Available in the Text.
摘要
补充数字内容可在文本中查看。
相似文献
1
Efficacy and Safety of Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) in Treatment-Naive Adults With HIV-1 and Transmitted Nonnucleoside Reverse Transcriptase Inhibitor Resistance Mutations.
J Acquir Immune Defic Syndr. 2019 Dec 1;82(4):e47-e49. doi: 10.1097/QAI.0000000000002153.
2
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. doi: 10.1097/QAI.0000000000002056.
3
Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus-1 Infection: Week 48 Results of the DRIVE-AHEAD Trial.
Clin Infect Dis. 2019 Feb 1;68(4):535-544. doi: 10.1093/cid/ciy540.
4
No meaningful drug interactions with doravirine, lamivudine and tenofovir disoproxil fumarate coadministration.
Antivir Ther. 2019;24(6):443-450. doi: 10.3851/IMP3324.
5
Comparative Bioavailability of Oral Granule Formulations of the HIV Antiretroviral Drugs Doravirine, Lamivudine, and Tenofovir Disoproxil Fumarate.
AAPS PharmSciTech. 2020 Feb 13;21(3):91. doi: 10.1208/s12249-020-1630-6.
6
Brief Report: Efficacy and Safety of Oral Islatravir Once Daily in Combination With Doravirine Through 96 Weeks for Treatment-Naive Adults With HIV-1 Infection Receiving Initial Treatment With Islatravir, Doravirine, and Lamivudine.
J Acquir Immune Defic Syndr. 2022 Sep 1;91(1):68-72. doi: 10.1097/QAI.0000000000002879. Epub 2021 Dec 8.
7
Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):535-40. doi: 10.1097/01.qai.0000245886.51262.67.
8
Commonly Transmitted HIV-1 Drug Resistance Mutations in Reverse-Transcriptase and Protease in Antiretroviral Treatment-Naive Patients and Response to Regimens Containing Tenofovir Disoproxil Fumarate or Tenofovir Alafenamide.
J Infect Dis. 2017 Mar 15;215(6):920-927. doi: 10.1093/infdis/jix015.
9
Brief Report: Switching to DOR/3TC/TDF Maintains HIV-1 Virologic Suppression Through Week 144 in the DRIVE-SHIFT Trial.
J Acquir Immune Defic Syndr. 2021 Jun 1;87(2):801-805. doi: 10.1097/QAI.0000000000002642.
10
Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial.
Lancet HIV. 2020 Jan;7(1):e16-e26. doi: 10.1016/S2352-3018(19)30336-4. Epub 2019 Nov 15.
引用本文的文献
1
Baseline survey of doravirine resistance among pregnant women with HIV.
Rev Esp Quimioter. 2025 Mar 3;38(2):139-141. doi: 10.37201/req/107.2024. Epub 2025 Feb 6.
2
Two-Drug Combination Antiretroviral Therapy for HIV-1: Case Series and Literature Review.
Hosp Pharm. 2024 Nov 5:00185787241293374. doi: 10.1177/00185787241293374.
3
K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine.
Viruses. 2024 Sep 20;16(9):1493. doi: 10.3390/v16091493.
4
Potential role of doravirine for the treatment of HIV-1-infected persons with transmitted drug resistance.
AIDS Res Ther. 2023 Feb 7;20(1):8. doi: 10.1186/s12981-023-00503-5.
5
High Prevalence of Doravirine Resistance in HIV-1-Infected Patients with Virological Failure to an NNRTI-Based Single-Tablet Regimen.
Infect Drug Resist. 2022 Jul 20;15:3857-3869. doi: 10.2147/IDR.S361012. eCollection 2022.
6
Approved HIV reverse transcriptase inhibitors in the past decade.
Acta Pharm Sin B. 2022 Apr;12(4):1567-1590. doi: 10.1016/j.apsb.2021.11.009. Epub 2021 Nov 16.
7
Impact of HIV-1 Resistance-Associated Mutations on Susceptibility to Doravirine: Analysis of Real-World Clinical Isolates.
Antimicrob Agents Chemother. 2021 Nov 17;65(12):e0121621. doi: 10.1128/AAC.01216-21. Epub 2021 Sep 27.
8
A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.
Clin Drug Investig. 2021 Jul;41(7):629-638. doi: 10.1007/s40261-021-01046-1. Epub 2021 Jun 21.
9
Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa.
J Int AIDS Soc. 2021 May;24(5):e25706. doi: 10.1002/jia2.25706.
10
In vitro cross-resistance to doravirine in a panel of HIV-1 clones harbouring multiple NNRTI resistance mutations.
J Antimicrob Chemother. 2021 Jan 1;76(1):130-134. doi: 10.1093/jac/dkaa401.
本文引用的文献
1
Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial.
J Acquir Immune Defic Syndr. 2019 Aug 1;81(4):463-472. doi: 10.1097/QAI.0000000000002056.
2
The global burden of HIV-1 drug resistance in the past 20 years.
PeerJ. 2018 May 25;6:e4848. doi: 10.7717/peerj.4848. eCollection 2018.
3
Doravirine: a review.
Curr Opin HIV AIDS. 2018 Jul;13(4):308-314. doi: 10.1097/COH.0000000000000471.
4
HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.
Lancet Infect Dis. 2018 Mar;18(3):346-355. doi: 10.1016/S1473-3099(17)30702-8. Epub 2017 Dec 5.
5
Rilpivirine and Doravirine Have Complementary Efficacies Against NNRTI-Resistant HIV-1 Mutants.
J Acquir Immune Defic Syndr. 2016 Aug 15;72(5):485-91. doi: 10.1097/QAI.0000000000001031.
6
Doravirine Suppresses Common Nonnucleoside Reverse Transcriptase Inhibitor-Associated Mutants at Clinically Relevant Concentrations.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2241-7. doi: 10.1128/AAC.02650-15. Print 2016 Apr.
7
Trends in use of genotypic resistance testing and frequency of major drug resistance among antiretroviral-naive persons in the HIV Outpatient Study, 1999-2011.
J Antimicrob Chemother. 2015 Aug;70(8):2337-46. doi: 10.1093/jac/dkv120. Epub 2015 May 15.
8
Safety, tolerability and pharmacokinetics of doravirine, a novel HIV non-nucleoside reverse transcriptase inhibitor, after single and multiple doses in healthy subjects.
Antivir Ther. 2015;20(4):397-405. doi: 10.3851/IMP2920. Epub 2014 Dec 3.
9
In vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.
Antimicrob Agents Chemother. 2015 Jan;59(1):590-8. doi: 10.1128/AAC.04201-14. Epub 2014 Nov 10.
10
Increase in transmitted resistance to non-nucleoside reverse transcriptase inhibitors among newly diagnosed HIV-1 infections in Europe.
BMC Infect Dis. 2014 Jul 21;14:407. doi: 10.1186/1471-2334-14-407.
Zotero 插件